Midas Inc  (MDS) Trade Now »     Rate MDS  -  Discuss MDS  -  Add to Watch List        

"After warning that it would only achieve the low end of its previous guidance range for 2009, Celgene (NASDAQ: CELG) sold off significantly," notes biotech expert John McCamant.

Nevertheless, in his The Medical Technology Stock Letter he sees the selloff as any opportunity, calling the company a "great growth story."

"Celgene pre-announced 1Q 09 revenues of $600 million, which was significantly below Wall Street consensus estimates of $640-$650 million.

Keeping up with what’s going on with Midas (MDS) these past few days in terms of SEC filings takes something of a scorecard. Last week, the company announced that its’ annual report — due last Thursday — would be late. And then a British investor who owns just over 8% of Midas stock filed this 13-D asking the company to drop its poison pill.

But it was this passage in the 10-K that the company did file on Monday that caught our attention. In a nutshell? A bad economy is good for franchisees:

Mahindra Defence Systems (MDS) on Tuesday (March 17) inaugurated its first Special Military vehicles (SMV) facility in Faridabad near New Delhi. “The SMV will manufacture specialised vehicles for the armed forces, paramilitary forces and the police and is also designed to undertake vehicle development, armouring and conversions,” Mahindra Group Vice Chairman and Managing Director Anand Mahindra told a press conference at the plant site. The SMV plant will be developed in two phases.